HR 8339 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Drug Origin Transparency Act of 2026
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Summary
This bill amends the Federal Food, Drug, and Cosmetic Act to increase transparency about drug manufacturing and supply chains. It requires drug manufacturers to submit enhanced reporting to the FDA that identifies suppliers of active pharmaceutical ingredients and in-process materials, and specifies the amounts of drugs manufactured using ingredients from each supplier. Reports must be submitted more frequently than annually, up to four times per year on a schedule set by the FDA. The bill also requires drug labels to include the name, place of business, and unique facility identifier of the original manufacturer and any other manufacturers involved in producing the drug or its active pharmaceutical ingredients. The FDA may allow reasonable variations in how labeling requirements are implemented, including through electronic means.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
3 cosponsors
- Rep. Crenshaw, Dan [R-TX-2] (R-TX)
- Rep. Hinson, Ashley [R-IA-2] (R-IA)
- Rep. Schrier, Kim [D-WA-8] (D-WA)
Money behind the sponsor
Top reported contributors to Doris O. Matsui’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- UC DAVIS $9,300
- DISH NETWORK $8,100
- NULL $7,800
- KORSHAK KRACOFF KONG & SUGANO LLP $6,600
- DOWNEY BRAND LLP $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Doris O. Matsui → · Outside spending →
Actions (2)
- Apr 16, 2026 Referred to the House Committee on Energy and Commerce. · house
- Apr 16, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
April 16, 2026
Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. Hinson) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Drug Origin Transparency Act of 2026”.
SEC. 2. ENHANCED DRUG MANUFACTURING AMOUNT INFORMATION REPORTING.
(a) In General.—Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended—
(1) in subparagraph (A), by adding “or (2)” after “paragraph (1)”; and
(2) by adding at the end the following:
“(C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall—
“(i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as—
“(I) the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and
“(II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in- process material from each such identified supplier; and
“(ii) be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year.
“(D) Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).”.
(b) Conforming Amendment.—Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 510(j)(3)(B)) is amended by striking “subparagraph (A)” and inserting “this paragraph”.
SEC. 3. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION.
Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
352) is amended—
(1) in paragraph (b)—
(A) by striking “(b) If in a package” and inserting “(b)(1) If in a package”;
(B) by striking “a label containing (1) the name and place” and inserting “a label containing—
“(A) the name and place”;
(C) by striking “or distributor; and (2) an accurate statement” and inserting “or distributor; and
“(B) an accurate statement”;
(D) by striking “under clause (2) of this paragraph” and inserting “under this clause”; and
(E) by inserting at the end the following:
“(2)(A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements.
“(B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient.
“(C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.”; and
(2) by inserting after paragraph (c) the following:
“(d)(1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of—
“(A) the original manufacturer of each active pharmaceutical ingredient;
“(B) each manufacturer, if different from the original manufacturer; and
“(C) the packer or distributor, if any.
“(2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.”. <all>
Comments